Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

antifungal

- PMLiVE

Pfizer resurrects its OTC bid for Viagra in the UK

Confirms MHRA review of new pharmacist-supplied status has begun

- PMLiVE

Merck, Pfizer get first OK for checkpoint inhibitor avelumab

FDA approval for rare skin cancer drug

- PMLiVE

Pfizer launches new antibiotic Zavicefta in UK and Germany

Biopharmaceutical company Pfizer releases MDR antibiotic

- PMLiVE

Servier cleared to start US trials CAR-T therapy

FDA rules studies of its Pfizer-partnered drug can be resumed

Deal Watch February 2017

Actelion, Johnson & Johnson, Sanofi, Takeda and more feature in this month's pharma deals round-up

Marketing strategy in complex environments

Age-old treatment protocols are being replaced with new and innovative treatment paradigms that will revolutionise the healthcare industry for years to come. Kulveer Singh and Mark Assenti talk through what...

Blue Latitude Health

- PMLiVE

Merck & Co and Pfizer take aim at diabetes with trio of new drugs

File ertugliflozin-based products with EU and US regulators

- PMLiVE

Pfizer strengthens board of directors

Ronald Blaylock brings financial and business leadership expertise

- PMLiVE

Novartis’ Zykadia nears first-line lung cancer label

Hopes to boost slow second-line sales to compete directly with Pfizer’s Xalkori and Roche’s Alecensa 

- PMLiVE

Argos hit as kidney cancer immunotherapy fails phase III trial

Study discontinued as data shows renal cell carcinoma vaccine unlikely to meet targets

- PMLiVE

FDA verdict on Pfizer’s breakthrough leukaemia drug due in August

Phase III trials results saw complete remission in 81% of patients in the treatment group

Roche Basel Switzerland

Roche’s lung cancer drug Alecensa wins EU approval

Monotherapy conditionally approved as second-line NSCLC treatment

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links